Cite
Bressler NM, Veith M, Hamouz J, et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br J Ophthalmol. 2021;doi: 10.1136/bjophthalmol-2021-319637.
Bressler, N. M., Veith, M., Hamouz, J., Ernest, J., Zalewski, D., Studnička, J., Vajas, A., Papp, A., Vogt, G., Luu, J., Matuskova, V., Yoon, Y. H., Pregun, T., Kim, T., Shin, D., Oh, I., Jeong, H., Kim, M. Y., & Woo, S. J. (2021). Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. The British journal of ophthalmology, . https://doi.org/10.1136/bjophthalmol-2021-319637
Bressler, Neil M, et al. "Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes." The British journal of ophthalmology vol. (2021). doi: https://doi.org/10.1136/bjophthalmol-2021-319637
Bressler NM, Veith M, Hamouz J, Ernest J, Zalewski D, Studnička J, Vajas A, Papp A, Vogt G, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Oh I, Jeong H, Kim MY, Woo SJ. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br J Ophthalmol. 2021 Oct 16; doi: 10.1136/bjophthalmol-2021-319637. Epub 2021 Oct 16. PMID: 34656987.
Copy
Download .nbib